Form 4: Neurogene Director Robert Baffi Granted 12,050 Stock Options

Neurogene Inc. director Robert Baffi received a grant of 12,050 non-qualified stock options with a vesting schedule over one year, as detailed in a recent SEC Form 4 filing.

Summary

• Neurogene Inc. (NGNE) director Robert Baffi was granted 12,050 non-qualified stock options on June 12, 2025.
• The exercise price for these options is $20.4 per share.
• The options will vest monthly, with 1/12 of the total shares vesting each month, beginning July 12, 2025.
• Full vesting of the options is expected by June 12, 2026, contingent on Mr. Baffi's continued service to the company.
• The granted options have an expiration date of June 12, 2035.
• The filing also includes a Power of Attorney, dated June 12, 2025, authorizing specific individuals to prepare and file SEC Forms 3, 4, and 5 on behalf of Robert Baffi.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns the director's interests with shareholders, but it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options to Director Robert Baffi aligns his long-term financial interests with those of Neurogene Inc.'s shareholders, incentivizing company performance.
• The vesting schedule encourages continued service and commitment from a key director.

Negatives

• The issuance of new stock options represents potential future dilution for existing shareholders if and when these options are exercised.

Future Outlook

The document primarily details a compensation event for a director, with the vesting schedule extending to June 2026, indicating a continued commitment from the director to the company's future performance.

Industry Context

This filing is a routine disclosure of insider compensation, common across publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Grant of 12,050 non-qualified stock options to Robert Baffi, a director of Neurogene Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential future dilution if the options are exercised, but also improved alignment of the director's interests with long-term shareholder value creation.
• Employees (specifically Robert Baffi): Receives equity compensation, incentivizing continued performance and retention.

Next Steps

• Monthly vesting of 1/12 of the granted options will commence on July 12, 2025.
• The options will continue to vest monthly until fully vested on June 12, 2026.

Key Dates

Keywords

Neurogene Inc., NGNE, Form 4, stock option grant, director compensation, insider transaction, equity incentive, Robert Baffi